https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-14 / Cancer Chemother. Pharmacol. 2013 Jul;72(1):139-462013-05-14 00:00:002013-05-14 00:00:00Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-05-01 / Anticancer Res. 2013 May;33(5):2047-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-05-01 / Anticancer Res. 2013 May;33(5):2047-562013-05-01 00:00:002019-02-15 08:34:51Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-04-30 / Int. J. Mol. Med. 2013 Jul;32(1):195-202
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-04-30 / Int. J. Mol. Med. 2013 Jul;32(1):195-2022013-04-30 00:00:002019-02-15 09:17:14Identification of common gene networks responsive to mild hyperthermia in human cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-04-19 / Cancer Immunol. Immunother. 2013 Jun;62(6):1083-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-04-19 / Cancer Immunol. Immunother. 2013 Jun;62(6):1083-912013-04-19 00:00:002019-02-15 08:52:30Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-04-16 / Cancer Immunol. Immunother. 2013 May;62(5):909-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-04-16 / Cancer Immunol. Immunother. 2013 May;62(5):909-182013-04-16 00:00:002019-02-15 08:48:36Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-04-14 / Evid Based Complement Alternat Med 2013;2013:672873
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-04-14 / Evid Based Complement Alternat Med 2013;2013:6728732013-04-14 00:00:002019-02-15 09:17:13Hyperthermia versus Oncothermia: Cellular Effects in Complementary Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-21 / Cancer Lett. 2013 Aug;336(2):253-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-21 / Cancer Lett. 2013 Aug;336(2):253-92013-03-21 00:00:002019-02-15 08:36:01Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-18 / J. Interferon Cytokine Res. 2013 Jul;33(7):346-542013-03-18 00:00:002013-03-18 00:00:00The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-β signaling
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-13 / PLoS One 2013;8(3):e59051
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-13 / PLoS One 2013;8(3):e590512013-03-13 00:00:002013-03-13 00:00:00A low selenium level is associated with lung and laryngeal cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-04 / Hum Vaccin Immunother 2013 Jun;9(6):1217-272013-03-04 00:00:002019-02-15 08:48:05Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study
